



13 to 17 September 2024  
Fira Barcelona Gran Via, Barcelona, Spain

The ESMO Congress is a globally influential oncology platform for clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world. It will disseminate the latest cutting-edge data, provide high quality education and excellent networking opportunities for oncologists and other stakeholders from all around the world.

Congratulations to our NCIS clinicians selected for presentations at #ESMO24.



## Mini Oral Presentation



**Dr Chong Wan Qin**  
Consultant  
Haematology-Oncology

Phase II open-label randomized study of pembrolizumab with or without bevacizumab in platinum-resistant recurrent/metastatic nasopharyngeal carcinoma (R/M NPC)

## Poster Presentation (Trials in Progress)



**Dr Robert Walsh**  
Associate Consultant  
Haematology-Oncology

A Phase II trial of a neural network-based treatment decision support tool in patients with refractory solid organ malignancies

## Poster Presentations



**Dr Natalie Ngoi**  
Consultant  
Haematology-Oncology

Pembrolizumab plus lenvatinib in recurrent clear cell gynecological cancer: Phase II LARA trial (GCGS-OV4/ APGOT-OV3)

Dr Ngoi is also a recipient of the ESMO Merit Travel Grant.



**Dr Jerold Loh**  
Senior Resident  
Haematology-Oncology

Machine learning models (MLM) predict venous thromboembolism events (VTE) in asian oncological inpatients better than the khorana score (KS)

Dr Loh is also a recipient of the ESMO Merit Travel Grant.



**Dr Manavi Sachdeva**  
Senior Resident  
Haematology-Oncology

Effect of Tumor Microenvironment B-Cell Abundance on Survival in Resectable Gastric Cancer: A Translational Analysis from the CLASSIC trial

GET LATEST UPDATES ON NCIS @ ESMO 2024

Follow #TEAMNCIS

[LinkedIn](#) | [X](#) | [Instagram](#) | [Facebook](#) | [YouTube](#)

[www.ncis.com.sg](http://www.ncis.com.sg)